Abstract 563P
Background
Osimertinib, the standard first-line therapy for EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC), preliminarily demonstrated similar clinical effectiveness to the landmark FLAURA study in the prospective, non-interventional, real-world FLOURISH study at the first interim analysis. This report presents an updated effectiveness and safety results.
Methods
A total of 500 patients were recruited into the FLOURISH study from 22 sites in China between July 27, 2020, and April 27, 2022. This analysis included 460 patients who met the eligibility criteria and received at least one dose of osimertinib after enrolment and without protocol violation into the full analysis set (FAS) for effectiveness analysis, and 495 patients who received at least one dose of osimertinib after enrolment into the safety set (SS). The data cut-off date was June 30, 2023.
Results
Of the 460 patients in FAS, the median age was 64.1 years (range: 27-88), 62.4% were female, 64.8% had comorbidities, 35.0% with CNS metastases, and 98.7% in stage IIIB-IV. The objective response rate (ORR) was 61.8% (238/385), and disease control rate (DCR) was 96.1% (370/385) in evaluable patients. With a median follow-up of 18.0 months, the 1-year progression-free survival (PFS) and 1-year overall survival (OS) rate was 79.6% (95%CI: 75.0%-83.3%) and 90.0% (95%CI: 86.8%-92.5%), respectively. In patients with CNS metastases, ORR was 63.8% (90/141), DCR was 95.0% (134/141), 1-year PFS rate was 78.9%, and 1-year OS rate was 90.1%. Moreover, patients with exon 19 deletion (n=235) had higher 1-year PFS (84.2% vs. 75.0%) and 1-year OS (93.4% vs. 86.8%) rates than patients with exon 21 L858R (n=212). Among the 495 patients in SS, 195 patients (39.4%) experienced adverse events (AEs), with 18(3.6%) of grade ≥3. AEs leading to dose interruption or discontinuation were reported in 3 (0.6%) and 12(2.4%) patients, respectively.
Conclusions
The FLOURISH study showed consistence with FLAURA in terms of effectiveness of first-line osimertinib for Chinese patients with advanced EGFRm-NSCLC in real world setting. No new safety signals were observed. The follow-up is still ongoing and the final analysis is expected in future.
Clinical trial identification
NCT04391283.
Editorial acknowledgement
Legal entity responsible for the study
Guangdong Association of Clinical Trials.
Funding
AstraZeneca China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
49P - Survival outcomes of HER2-positive breast cancer patients treated with neoadjuvant therapy at a single cancer centre in India
Presenter: Minit Shah
Session: Poster Display
Resources:
Abstract
50P - A nationwide retrospective cohort study of the response to neoadjuvant chemotherapy between HER-2 low and HER-2 negative non-metastatic breast cancer in Qatar: A real-world analysis
Presenter: Ahmed Kardousha
Session: Poster Display
Resources:
Abstract
51P - Four-year outcomes of hypofractionated postmastectomy radiation therapy of 39 Gy in 13 fractionations
Presenter: Sevinj Gahramanova
Session: Poster Display
Resources:
Abstract
52P - A comparative study to assess volumetric and dosimetric profile of heart and lung in patients undergoing left sided post mastectomy radiotherapy: Continuous positive airway pressure (CPAP) versus free breathing (FB) techniques
Presenter: Pritanjali Singh
Session: Poster Display
Resources:
Abstract
29P - HUWE1 inhibition has tumor suppressive effect in triple-negative breast cancer cell lines by modulating glycolytic and immune modulatory markers
Presenter: Shruti Kahol
Session: Poster Display
Resources:
Abstract
53P - Radiotherapy utilization rate for breast cancer in Indonesia: A call for empowering cancer care
Presenter: Donald Manuain
Session: Poster Display
Resources:
Abstract
58P - Safety and pharmacokinetics (PK) of vepdegestrant in Japanese patients with estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: Results from a Japanese phase I study
Presenter: Hiroji Iwata
Session: Poster Display
Resources:
Abstract
59P - Comprehensive genomic profiling (CGP) unravels druggable targets in breast carcinoma (BC): A single institutional experience
Presenter: Gautam Balaram
Session: Poster Display
Resources:
Abstract
60P - A study of gene alterations in Asian patients with late stage and recurrent breast cancer
Presenter: Po-Sheng Yang
Session: Poster Display
Resources:
Abstract
61P - Tumor cell-released autophagosomes (TRAPs) remodel the breast tumor microenvironment by inducing the formation of inflammatory cancer-associated fibroblasts (CAFs)
Presenter: Chengdong Wu
Session: Poster Display
Resources:
Abstract